publicly traded biopharmaceutical company headquartered in San Diego, CA, with a twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "MSTX began dosing in its pivotal Phase 3 clinical study of MST-188 (purified poloxamer 188) in sickle cell disease in May. MSTX believes that it is currently the only company with a new molecular entity in a Phase 3 clinical trial for the treatment of sickle cell disease, a disease with significant unmet needs and which has been experiencing unprecedented interest from strategic partners, acquisition oriented suitors, and financial investors." Mr. Silver continued, "MSTX plans to develop MST-188 in complications of arterial disease, initially as an adjunct to thrombolytics in acute limb ischemia (ALI), a complication of peripheral arterial disease. Peripheral arterial disease affects an estimated 8 to 12 million people in the United States. The planned Phase 2 trial in ALI is scheduled to commence in the first quarter of 2014." Mr. Silver concludes, "MSTX anticipates that cash as of September 30, 2013 or $0.48/share, should be sufficient to fully fund all planned clinical trials."
They help smart people load on the cheap. Please keep saying non sense so I can buy more. This stock is idiot proof, it is selling below its cash value + tons of clinical research that is worth millions of dollars. ~Smile
Sentiment: Strong Buy
DSCO is in a difficult position competing with top boys. The launch expenses is high. I would be worried if I'm in your place. MSTX is below cash value plus all the clinical work they did. Think before you post. Another empty post by an ignorant.
For the last two weeks Rosg has positive news, especially today. Thumbs up to ROSG. Shorts will be covering and MM will be adding.
This stock has shorts exceeding 10% and institution low holdings. that means shouting up big time.
again mrket cap really low for such an innovation company. wait to see upgrades soon.
Do you know how much and how long a phase 3 takes. you are looking at 2 years. Need 200 million for this development to finish. We are looking at secondary IPO soon at 7.00 dollars.
lots of money and effort needed to call this a bio pharma company. I sold my 2000 shares at $2.13. I think people do not understand this and buying with the crowd. day traders ....